0001415889-24-006475.txt : 20240304 0001415889-24-006475.hdr.sgml : 20240304 20240304212222 ACCESSION NUMBER: 0001415889-24-006475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240304 DATE AS OF CHANGE: 20240304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cowan Elvia CENTRAL INDEX KEY: 0001960048 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 24717998 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, SUITE 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 form4-03052024_020305.xml X0508 4 2024-02-29 0001649094 Vaxcyte, Inc. PCVX 0001960048 Cowan Elvia C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, SUITE 300 SAN CARLOS CA 94070 false true false false SVP, FINANCE 1 Common Stock 2024-02-29 4 A 0 5400 0 A 13158 D Common Stock 2024-03-01 4 M 0 11000 25.92 A 24158 D Common Stock 2024-03-01 4 S 0 2322 73.084 D 21836 D Common Stock 2024-03-01 4 S 0 4455 73.689 D 17381 D Common Stock 2024-03-01 4 S 0 4901 74.9 D 12480 D Common Stock 2024-03-02 4 F 0 324 71.55 D 12156 D Stock Option (right to buy) 73.82 2024-02-29 4 A 0 25000 0 A 2024-02-28 Common Stock 25000 25000 D Stock Option (right to buy) 25.92 2024-03-01 4 M 0 11000 0 D 2032-08-08 Common Stock 11000 129000 D Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on August 31, 2024 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Includes 457 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $72.39 to $73.365. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. 1/48 of shares subject to the option vest on March 31, 2024, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. /s/ Ron A. Metzger, Attorney-in-Fact 2024-03-04